Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates

Addiction

Volumn 107, Issue SUPPL.1, 2012, Pages 53-62

  Gaalema, Diann E ^a   Scott, Teresa Linares ^b   Heil, Sarah H ^a,b   Coyle, Mara G ^c   Kaltenbach, Karol ^d   Badger, Gary J ^a   Arria, Amelia M ^e   Stine, Susan M ^f   Martin, Peter R ^g   Jones, Hendrée E ^h,i  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

^c BROWN UNIVERSITY   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g VANDERBILT UNIVERSITY   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ RTI INTERNATIONAL   (United States)

Author keywords

Buprenorphine; In utero; Incidence; Methadone; Neonatal abstinence syndrome; Profile; Severity; Signs; Treatment initiation

Indexed keywords

BUPRENORPHINE; METHADONE; NARCOTIC ANALGESIC AGENT;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INCIDENCE; MULTICENTER STUDY; NEWBORN; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PATHOPHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL EXPOSURE; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; STATISTICS; SYMPTOM ASSESSMENT; TIME; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADULT; ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; BUPRENORPHINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INCIDENCE; INFANT, NEWBORN; METHADONE; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; SEVERITY OF ILLNESS INDEX; SYMPTOM ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 84868097071     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2012.04039.x     Document Type: Article

References (39)

1. Hulse G. K., Milne E., English D. R., Holman C. D. J. The relationship between maternal use of heroin and methadone and infant birth weight. Addiction 1997; 92: 1571-1579.
2. Kandall S. R., Albin S., Gartner L. M., Lee K.-S., Eidelman A., Lowinson J. The narcotic-dependent mother: fetal and neonatal consequences. Early Hum Dev 1977; 1: 159-169.
3. Lester B. M., Andreozzi L., Appiah L. Substance use during pregnancy: time for policy to catch up with research. Harm Reduct J 2004; 1: 5-49.
4. Lifschitz M. H., Wilson G. S., Smith E. O., Desmond M. M. Factors affecting head growth and intellectual function in children of drug addicts. Pediatrics 1985; 75: 269-274.
5. Messinger D. S., Bauer C. R., Das A., Seifer R., Lester B. M., Lagasse L. L. etal. The Maternal Lifestyle Study: cognitive, motor, and behavioral outcomes of cocaine-exposed and opiate-exposed infants through three years of age. Pediatrics 2004; 113: 1677-1685.
6. Winklbaur B., Kopf N., Ebner N., Jung E., Thau K., Fischer G. Treating pregnant women dependent on opioids is not the same as treating pregnancy and opioid dependence: a knowledge synthesis for better treatment for women and neonates. Addiction 2008; 103: 1429-1440.
7. Jones H. E., O'Grady K. E., Malfi D., Tuten M. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict 2008; 17: 372-386.
8. Kaltenbach K., Berghella V., Finnegan L. Opioid dependence during pregnancy: effects and management. Obstet Gynecol Clin North Am 1998; 25: 139-151.
9. Finnegan L. P., Kaltenbach K. Neonatal abstinence syndrome. In: Hoekelman R. A., Friedman S. B., Nelson N. M., Weitzman M. L., Wilson M. H., editors. Primary Pediatric Care, 2nd edn. St Louis: Mosby; 1992, p. 1367-1378.
10. Mattick R. P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008; 16 CD002207.
11. Fudala P. J., Jaffe J. H., Dax E. M., Johnson R. E. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 1990; 47: 525-534.
12. Jasinski D. R., Pevnick J. S., Griffith J. D. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch Gen Psychiatry 1978; 35: 501-516.
13. Johnson R. E., Strain E. C., Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend 2003; 70: S59-77.
14. Mello N. K., Mendelson J. H. Buprenorphine suppresses heroin use by heroin addicts. Science 1980; 207: 657-659.
15. Walsh S. L., Eissenberg T. The clinical pharmacology of buprenorphine extrapolating from the laboratory to the clinic. Drug Alcohol Depend 2003; 70: S13-27.
16. Bakstad B., Sarfi M., Welle-Strand G. K., Ravndal E. Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. Eur Addict Res 2009; 15: 128-134.
17. Binder T., Vavrinkova B. Prospective randomized comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department. Neuro Endocrinol Lett 2008; 29: 80-86.
18. Fischer G., Ortner R., Rohrmeister K., Jagsch R., Baewert A., Langer M. etal. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006; 101: 275-281.
19. Jones H. E., Johnson R. E., Jasinski D. R., O'Grady K. E., Chisolm C. A., Choo R. E. etal. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005; 79: 1-10.
20. Kakko J., Heilig M., Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 2008; 96: 69-78.
21. Lejeune C., Simmar-Durand L., Gourarier L., Aubisson S., Groupe d'Etudes Grossesse et Addictions (GEGA). Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenorphine substitution. Drug Alcohol Depend 2006; 82: 250-257.
22. Jones H. E., Kaltenbach K., Heil S. H., Stine S. M., Coyle M. G., Arria A. M. etal. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363: 2320-2331.
23. Jones H. E., Fischer G., Heil S. H., Kaltenbach K., Martin P. R., Coyle M. G. etal. Maternal Opioid Treatment: Human Experimental Research (MOTHER)-approach, issues, and lessons learned. Addiction 2012; 107 (Suppl. 1): 28-35.
24. Jansson L. M., Velez M., Harrow C. The opioid-exposed newborn: assessment and pharmacologic management. J Opioid Manag 2009; 5: 47-55.
25. Glass G. V., Peckham P. D., Sanders J. R. Consequences of failure to meet assumptions underlying the fixed effects analyses of variance and covariance. Rev Educ Res 1972; 42: 237-288.
26. Stiger T. R., Kosinski A. S., Barnhart H. X., Kleinbaum D. G. ANOVA for repeated ordinal data with small sample size-a comparison of ANOVA, MANOVA, WLS and GEE methods by simulation. Commun Stat B Simul Comput 1998; 27: 357-375.
27. Kolb L., Himmelsbach C. K. Clinical studies of drug addiction, III: a critical review of the withdrawal treatments with method of evaluating abstinence syndromes. Am J Psychiatry 1938; 94: 759-799.
28. Himmelsbach C. K. Further studies of the addiction liability of Demerol. J Pharmacol Exp Ther 1943; 79: 5- 9.
29. American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics 1998; 101: 1079-1088.
30. Substance Abuse and Mental Health Services Administration/Center for Substance Abuse Treatment (SAMHSA/CSAT). Treatment Improvement Protocol 5: Improving Treatment for Drug-Exposed Infants. Center for Substance Abuse Treatment. Rockville, MD: Substance Abuse and Mental Health Services Administration; 1993.
31. Coles L. D., Lee I. J., Hassan H. E., Eddington N. D. Distribution of saquinavir, methadone, and buprenorphine in maternal brain, placenta, and fetus during two different gestational stages of pregnancy in mice. J Pharm Sci 2009; 98: 2832-2846.
32. Nanovskaya T., Deshmukh S., Brooks M., Ahmed M. S. Transplacental transfer and metabolism of buprenorphine. J Pharmacol Exp Ther 2002; 300: 26-33.
33. Nekhayeva I. A., Nanovskaya T. N., Deshmukh S. V., Zharikova O. L., Hankins G. D., Ahmed M. S. Bidirectional transfer of methadone across human placenta. Biochem Pharmacol 2005; 69: 187-197.
34. Boas R. A., Villiger J. W. Clinical actions of fentanyl and buprenorphine. Br J Anaesth 1985; 57: 192-196.
35. Walsh S. L., Preston K. L., Bigelow G. E., Stitzer M. L. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 1995; 274: 361-372.
36. Hughes P. H., Rieche O. Heroin epidemics revisited. Epidemiol Rev 1995; 17: 66-73.
37. Finnegan L. P., Kron R. E., Connaughton J. F., Emich J. P. Assessment and treatment of abstinence in the infant of the drug-dependent mother. Int J Clin Pharmacol 1975; 12: 19-32.
38. Jones H. E., Harrow C., O'Grady K. E., Crocetti M., Jansson L. M., Kaltenbach K. Neonatal abstinence scores in opioid-exposed and nonexposed neonates: a blinded comparison. J Opioid Manag 2010; 6: 409-414.
39. D'Apolito K. A scoring system for assessing neonatal abstinence syndrome [video tapes and manual]. Seattle: University of Washington, School of Nursing, 1994.